NJ Cannabis Media -
October 5, 2018

FDA recommended CBD be classified as Schedule V drug

Written by Marc Schwarz
Facebooktwittergoogle_plusredditpinterestlinkedinmail

Cannabidiol (CBD) should be reassigned to Schedule V, the least restrictive class of the Controlled Substances Act, according to a 27-page Food and Drug Administration agency memo written earlier this year and first reported by MarijuanaMoment.com.

In the memo titled, “Basis for the Recommendation to Place Cannabidiol in Schedule V of the Controlled Subtsance Act, the FDA wrote “CBD and its salts… do not have a significant potential for abuse and could be removed from the [Controlled Substances Act].”

CBD, as with all cannabis products, is currently Schedule I, the most restrictive classification – the same as heroin and LSD and cannot be legally marketed in the United States.

The reason the FDA suggested reclassification to Schedule V instead of removal from the CSA is due to international drug treaties that require the U.S. to control the cannabis extract.

The report, which included a letter from Dr. Brett Giroir, the assistant secretary for health in the U.S. Health and Human Services Department, FDA’s parent agency, also said “if treaty obligations do not require control of CBD, or if the international controls on CBD change in the future, this recommendation will need to be promptly revisited” and CBD should be declassified.

The letter was dated May 16 but made public Sept. 28, after the DEA announced that FDA-approved Epidiolex and any potentially other cannabis drugs with no more than 0.1 percent THC could be classified as Schedule 5.

The potential for the CBD market is immense.

According to a new report released recently by the Brightfield Group, the hemp-derived CBD market (which is legal) alone will reach sales of $22 billion by 2022, outpacing cannabis sales, and surging from $591 million in 2018.

To read the memo:

OTHER NEWS

NY says it can raise up to $678 million in tax revenue

July 16, 2018
A new report by the New York State Department of Health estimates...

Health commissioner continues grand rounds

July 16, 2018
New Jersey Health Commissioner Dr. Shereef Elnahal encouraged doctors...

New bill would make state legalized marijuana federally lawful

June 3, 2018
The affects of the federal prohibition of cannabis on the New Jersey...

New guidance from AG on municipal court prosecutions

August 31, 2018
New Jersey prosecutors are not permitted to adopt their own policies...